HEAD & NECK CANCERS

The FDA designates ficerafusp alfa as a breakthrough therapy for treating HPV-negative head and neck cancer, enhancing patient outcomes and options.

Innovative NBTXR3 shows promise in enhancing radiotherapy for recurrent head and neck cancer, potentially transforming treatment options for patients.

A subanalysis of the VERSATILE-002 study highlights significant survival benefits for HNSCC patients with low PD-L1 expression using PDS0101 and pembrolizumab.

The FDA fast-tracks CRB-701, an innovative ADC for advanced head and neck cancer, showing promising efficacy and safety in ongoing trials.

Eftilagimod alfa shows promise as a novel immunotherapy for head and neck cancer patients with low PD-L1 expression, offering new treatment hope.

During a live event, Deborah Wong, MD, PhD, discussed the role of PD-1 inhibitors in nasopharyngeal cancer and their accessibility/safety.

Nivolumab with cisplatin and radiotherapy improved disease-free survival in high-risk locally advanced squamous cell carcinoma of the head and neck in the NIVOPOSTOP trial.

During a live event, Deborah Wong, MD, PhD, discussed the role of EBV and challenges in nasopharyngeal cancer diagnosis with event participants.

Reduced-dose radiotherapy in head & neck cancer shows similar efficacy to standard dose but with lower toxicity, per findings from the UPGRADE-RT trial.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head and neck cancer per KEYNOTE-689, introducing a potential new standard of care.

The FDA has approved penpulimab with chemotherapy for first-line recurrent/metastatic non-keratinizing nasopharyngeal carcinoma and alone after prior treatment.

Neoadjuvant nivolumab/chemotherapy followed by response-stratified de-escalated chemoradiation showed strong potential in HPV-negative head and neck cancer.

Deborah Wong, MD, PhD, discusses therapeutic options for patients with nasopharyngeal carcinoma.

Palliative care consultations in esophageal cancer improved QOL and reduced financial burden, according to ASCO GI poster findings.

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

Evidence suggests that extranodal extension on radiological imaging is a negative prognostic factor in head and neck cancer, but diagnostic criteria and terminology have been unclear.

Camrelizumab increased the 3-year event-free survival rate vs standard of care from 77.3% to 86.9%, translating to a 44% reduced risk of death or relapse in patients with nasopharyngeal carcinoma.

Neoadjuvant chemotherapy prior to surgery and postoperative radiation therapy could improve organ preservation in patients with T3 and T4a nasal and paranasal sinus squamous cell carcinoma.

Christina Henson, MD, discusses how new guidelines for head and neck cancer imaging could change dynamics for physicians and patients.

Elizabeth Franzmann, MD, discusses findings of a study exploring a novel method of testing recurrence of head and neck cancer.

Christina Henson, MD, discussed proposed guidelines for head and neck cancer imaging to improve patient outcomes and consistency across practices.

With this designation, the sponsor of APG-157 is eligible for more frequent interaction with the FDA, facilitating faster drug development and review for this neoadjuvant head and neck cancer therapy.

A phase 2 trial will assess BRG01 for the treatment of patients with relapsed/metastatic EBV-positive nasopharyngeal carcinoma.

Christina Henson, MD, discusses unmet needs among patients with head and neck cancer.

Gedeptin, a novel gene therapy, is entering phase 2 clinical trials to evaluate its efficacy in treating recurrent head and neck cancer.